Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin in Non-Hodgkin's Lymphomas
NCT00542919Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of enzastaurin in non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Tumor Response Rate (RR) up to 114 Months. Started Nov 2007; status: completed.
02
Drugs
enzastaurin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00542919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542919.